Tandem Diabetes Care, Inc. (TNDM) Stock Grade

About Tandem Diabetes Care, Inc.'s fundamentals

Tandem Diabetes Care is a $1.1 billion medical device company with revenue growing at 7.9% year-over-year, indicating steady expansion in its core business. However, the company is currently unprofitable, operating at a net margin of -20.2% and reporting a net loss in its latest annual statement. With no dividend yield, the company is reinvesting any available capital back into operations rather than returning funds to shareholders. The lack of meaningful profitability metrics reflects the company's early-stage or investment-heavy phase typical of growth-focused healthcare device manufacturers.